Figure 4.

Three-dimensional clustered rank plot. Values of each axis are the probabilities which antiplatelet regimens had the first ranking for recurrent stroke, composite outcomes, and major bleeding event using values of surface under the cumulative ranking curve. The point (1, 1, 1) is the hypothetical point with 100% probability of first ranking for all interesting events. Since cilostazol is the closest antiplatelet therapy regimen to the point (1, 1, 1), it was considered to have the greatest net clinical benefit.